RHOC and non-small cell lung carcinoma: Another important finding of this study is that Rhoc antibodies can be delivered into NSCLC cells by AP2 complexes and then mediate the degradation of Rhoc proteins in NSCLC cells, leading to the inhibition of tumor progression.